Bell2Bell’s latest podcast features Eric Weisblum, Founder and CEO of Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company.

Throughout the interview, Weisblum discussed Silo Pharma’s business model and recent milestones.

“Silo Pharma is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders,” Weisblum said. “We typically identify assets and look to partner with academic universities to advance their research with the goal of developing therapeutics to help patients down the road.”